Skip to search formSkip to main contentSkip to account menu

sabcomeline

Known as: alpha-(methylimino)-1-azabicyclo(2.2.2)octane-3-acetonitrile 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IminesQuinuclidines

Narrower (1)

SB 202026

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
The limited effect of AChE inhibitors and NMDA receptor antagonists for the treatment of the cognitive symptoms of Alzheimer's… 
2007
2007
Mono and combination therapy with M1/M4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
The invention relates to the use of a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof to treat… 
2005
2005
Sabcomeline as a single agent for the treatment of bipolar disorder sabcomeline or when used in combination with mood stabilizing or antimanic agent
本発明は、双極性障害または躁病を治療するための単剤療法におけるサブコメリンまたはそれらの製薬上許容できる塩の使用、および／または、双極性障害または躁病を治療するための補助療法的な、および、同時の併用療法に関し、本方法において、サブコメリンまたはそれらの製薬上許容できる塩、および、少なくとも１種のその他の気分安定剤または抗躁病薬は、補助療法的に、または、同時に投与される。 本発明は、このような単剤療法、および、このような補助療法的な、または、同時の治療的な併用療法、そこで使用するための治療の組み合わせ、および、それらを含む医薬組成物を利用する、双極性障害または躁病の治療方法を提供する。 
2003
2003
Effect of sabcomeline on muscarinic and dopamine receptor binding in intact mouse brain
Sabcomeline [(R,-(Z)-(+)-α-(methoxyiamino)-1-azabicyclo[2.2.2.]octane-3-acetonitrile)] is a potent and functionally selective… 
2001
2001
Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.
2001
2001
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
Carbamylcholine, a nonselective muscarinic receptor agonist, and sabcomeline and xanomeline, functional M(1) receptor-selective… 
1999
1999
Muscarinic Receptor Agonists in Alzheimer’s Disease
Research into and development of selective muscarinic receptor agonists for the treatment of Alzheimer’s disease is based on the… 
1999
1999
Counteractive effects of a partial (Sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial…
1999
1999
In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes.
1998
1998
Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze
Abstract Sabcomeline, (SB-202026 [R-(Z)-α-(methoxyimino)-1-azabicyclo [2.2.2] octane-3-acetonitrile]), a functionally selective… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)